Mogrify is a UK biotechnology company whose mission is to transform the development of ex vivo cell therapies, as well as pioneer a new class of in vivo reprogramming therapies. The Company has developed a proprietary direct cellular conversion platform that, for the first time, makes it possible to both systematically enhance the efficiency of stem cell-derived reprogramming and directly convert (transdifferentiate) mature cell types into other mature cell types (or states) without going through a pluripotent stem cell- or progenitor cell-state. Mogrify is applying its award-winning platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to develop ex vivo cell therapies or in vivo reprogramming therapies for indications of high unmet clinical need in oncology, ophthalmology and other disease areas. The platform is protected by the foundational patent application and a suite of additional patent applications covering improvements to the core platform and specific cell conversions. The Company is commercializing this via a business model of internal cell therapy development, co-development partnerships, and licensing of novel cell conversions to partners engaged in cell therapy development and regenerative medicine ($39 billion market USD by 2023). Mogrify was founded in 2016 and is headquartered in Cambridge, United Kingdom.
Something looks off?